Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 86

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 86
---
867 $32.97 Performance Share Units 

15

The following table summarizes performance share unit (PSU) activities:Performance-Based UnitsMarket-Based UnitsTotal PSUs Number of PSUsWeightedAverageGrant Date Fair Value per ShareNumber of PSUsWeightedAverageGrant Date Fair Value per ShareNumber of PSUsWeightedAverageGrant Date Fair Value per ShareNonvested, December 31, 2024324,685 $28.80 20,000 $28.63 344,685 $28.79 Granted— $— — $— — $— Vested(111,065)$30.52 — $— (111,065)$30.52 Forfeited(35,900)$30.26 — $— (35,900)$30.26 Nonvested, March 31, 2025 (unaudited)177,720$27.43 20,000$28.63 197,720$27.55 

10.    Earnings (Loss) per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the three months ended March 31, 2025 and 2024 (dollars in thousands, except share and per share amounts):Three Months EndedMarch 31,20252024(unaudited)Numerator:Net earnings (loss)$(11,827)$124 Denominator:Weighted average shares outstanding, basic55,864,692 54,801,748 Effect of dilutive securities:Stock options and stock awards— 824,915 Weighted average shares outstanding, diluted55,864,692 55,626,663 Earnings (Loss) per share, basic$(0.21)$0.00 Earnings (Loss) per share, diluted$(0.21)$0.00 The following table sets forth the common stock equivalents of outstanding stock-based awards excluded in the calculation of diluted earnings (loss) per share, because their inclusion would be anti-dilutive:Three Months EndedMarch 31,20252024(unaudited)Stock options and stock awards505,385 520,152 

11.    Income Tax Expense 

The following table provides information regarding the Company’s income tax expense for the three months ended March 31, 2025 and 2024 (dollars in thousands):Three Months EndedMarch